Navigation Links
Annual SNM MI summit introduces the clinical trials network
Date:1/13/2009

RESTON, Va.SNM will devote its annual Molecular Imaging Summit to introducing the new SNM Clinical Trials Network, Feb. 8𔃇, 2009, at the Hilton Clearwater Hotel, Clearwater, Fl. In part, the program will explain requirements of participation in the Clinical Trials Network, which was designed to facilitate cost-effective drug development through the integration of imaging biomarkers into Phase 1, 2, 3 and 4 therapeutics clinical trials. In addition, the workshop will explore key issues involved with imaging participation in multi-center trials.

"Attendance at this workshop is a must for imaging centers, pharmaceutical manufacturers and others who wish to be involved with the SNM's Clinical Trials Network," said Robert W. Atcher, Ph.D., M.B.A, president of SNM. "This intensive two-day program will outline the nuts and bolts of the network and requirements for participation."

The goal of SNM's Clinical Trials Network is to bring together the pharmaceutical industry, the imaging community, biomarker manufacturers and regulatory agencies and provide them with processes, standards and protocols to streamline the use of imaging in the development and testing processes for new pharmaceuticals. The use of imaging in clinical trials can help pharmaceutical developers determine earlier in the development process whether a new product is clinically promisingaccelerating the development of these promising drugs and eliminating those without apparent patient benefit. However, including these investigational imaging biomarkers in clinical trials for investigational therapeutics poses challenges for a drug development company, including a lack of standardized imaging methods and challenging regulatory approval or paperwork requirements for the imaging biomarker.

Several discussions between FDA and SNM have surfaced on this issue of limited harmonization of imaging protocols between multiple imaging centers. The use of a consistent methodology and protocol is key to quality data generation and ultimate FDA approval of investigational therapeutics.

"It is important that interested imaging centers, drug manufacturers and other facilities get involved at this time as there are steps to be taken to ensure imaging standardization and to maintain imaging quality control across multiple sites," added Atcher. "This workshop will give members of the molecular imaging community an overview of the network and specific steps that participating imaging sites can take to ensure that they are qualified for participation in therapeutic clinical trialsand remain qualified over time. Speakers from the Food and Drug Administration, National Cancer Institute, pharmaceutical development industry and the imaging community will share their thoughts on specific needs for imaging biomarkers in drug development and the unique issues involved with incorporating imaging into multi-center clinical trials.

This comprehensive workshop will be held immediately after SNM's Mid-Winter Educational Symposium. It is slated to include presentations and discussions about: methods and short-comings of current drug development practices; the potential for imaging biomarkers in multi-center clinical trials; the role of the Clinical Trials Network in drug development; and fundamentals of participation in this network. SNM will discuss the specific goals and detailed plans of the Clinical Trials Network, including the roles and responsibilities of participation in network imaging and manufacturing registries, the phantom program and the 2009 F-18-fluorothymidine (FLT) demonstration project. Representatives from drug trial sponsors will discuss the specific needs for imaging in multi-center clinical trials.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Covance to Present at the 27th Annual J.P. Morgan Healthcare Conference
2. Agito Networks Earns INTERNET TELEPHONY Magazines 11th Annual Product of the Year Award
3. Abaxis, Inc. to Present at Sidoti & Companys Sixth Annual Palm Beach Emerging Growth Institutional Investor Forum
4. WebMD to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. drugstore.com to Present at the 11th Annual ICR XChange Conference
6. Hop the Trolley for DNAs 27th Annual Conference
7. Almost Family to Present at 27th Annual J.P. Morgan Healthcare Conference
8. Society of Gynecologic Oncologists to Host 40th Annual Meeting on Womens Cancer
9. Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue
10. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
11. VNUS Medical Technologies to Present at 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center ... Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite ... This newest location will provide patients living in the north Houston area (The Woodlands, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The IoT ... and WiFi connectivity are making a huge impact on businesses and individual consumers alike. ... estimates the IoT will have a value anywhere from $4 trillion to $11 trillion ...
(Date:3/23/2017)... ... ... of adults are unaware of the dangers that infectious bacteria play in mouth disease, while ... a day that dentists recommend. The ramifications of improper oral upkeep go far beyond bad ... 164 million hours of work each year due to dental issues. That is why Mediaplanet ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and ... health. Every day, two kidneys filter about 120 to 150 quarts of blood. Put ... waste, regulating fluid levels and blood pressure, supporting bone health and promoting red blood ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: